Ignite Creation Date:
2024-05-06 @ 12:27 AM
Last Modification Date:
2024-10-26 @ 10:50 AM
Study NCT ID:
NCT01579994
Status:
COMPLETED
Last Update Posted:
2020-12-30
First Post:
2012-04-16
Brief Title:
Crizotinib and Ganetespib STA-9090 in ALK Positive Lung Cancers
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase I Study of Crizotinib and Ganetespib STA-9090 in ALK Positive Lung Cancers
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
About 18 patients will take part in the phase 1 portion of the trial In the beginning of the study 3 patients will be treated with a low dose of ganetespib STA-9090 and the standard dose of crizotinib If this dose does not cause significant side effects it will be increased as new patients take part in the study The study will only be open at Memorial Sloan Kettering Cancer Center
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None